Sharat C Raju1, Samantha J Hauff1, Aaron J Lemieux1, Ryan K Orosco1, Andrew M Gross2, Linda T Nguyen1, Elamprakash Savariar3, William Moss1, Michael Whitney3, Ezra E Cohen4, Scott M Lippman4, Roger Y Tsien5, Trey Ideker6, Sunil J Advani7, Quyen T Nguyen8. 1. Division of Head and Neck Surgery, University of California, San Diego, CA, USA. 2. Bioinfomatics and Systems Biology, University of California, San Diego, CA, USA. 3. Department of Pharmacology, University of California, San Diego, CA, USA. 4. Moores Cancer Center, San Diego, CA, USA. 5. Department of Pharmacology, University of California, San Diego, CA, USA; Howard Hughes Medical Institute, San Diego, CA, USA. 6. Bioinfomatics and Systems Biology, University of California, San Diego, CA, USA; Division of Medical Genetics, University of California, San Diego, CA, USA. 7. Department of Radiation Medicine and Applied Sciences, University of California, San Diego, CA, USA. 8. Division of Head and Neck Surgery, University of California, San Diego, CA, USA; Department of Pharmacology, University of California, San Diego, CA, USA; Moores Cancer Center, San Diego, CA, USA. Electronic address: q1nguyen@ucsd.edu.
Abstract
OBJECTIVE: Patients with head and neck squamous cell carcinoma (HNSCC) containing TP53 mutation and 3p deletion ("double-hit") have poorer prognosis compared to patients with either event alone ("single-hit"). The etiology for worse clinical outcomes in patients with "double-hit" cancers is unclear. We compared radiosensitivity of cell lines containing both TP53 mutations and deletion of Fragile Histidine Triad (FHIT, the gene most commonly associated with 3p deletion) to "single-hit" lines with only TP53 mutation. We compared radiosensitivity in a "single-hit" cell line with TP53 mutation converted to "double-hit" using RNA interference targeting FHIT. Finally, we compared matrixmetalloproteinase-2/9 (MMP-2/9) activity, a previously-established biomarker for tumor aggressiveness, in xenograft tumors derived from these cell lines. MATERIALS/ METHODS: TP53 mutation and FHIT deletion profiles of HNSCC lines were established using Cancer Cell Line Encyclopedia (CCLE). We used RNA-interference to convert a "single-hit" cell line (SCC4) to "double-hit". Cultured cells were examined for radiosensitivity and cisplatin sensitivity. MMP-2/9 activity was evaluated in "double-hit" versus "single-hit" tumors using ratiometric activatable cell-penetrating peptide (RACPP) in tongue (n=17) and flank xenografts (n=4). RESULTS: Radiotherapy caused greater double-stranded DNA breaks in "single-hit" vs naturally occurring and engineered "double-hit" cells. In-vivo, "double-hit" xenografts demonstrated higher MMP-2/9 activity compared to "single-hit" xenografts (p<0.01). There was no difference in cisplatin sensitivity between the cell lines. CONCLUSIONS: TP53 mutation combined with FHIT deletion correlates with decreased radiosensitivity in HNC cell lines. Xenograft from "double-hit" cells exhibit increased MMP-2/9 activity. These findings may in part account for the worse clinical outcome seen in patients with HNSCC "double-hit" tumors.
OBJECTIVE:Patients with head and neck squamous cell carcinoma (HNSCC) containing TP53 mutation and 3p deletion ("double-hit") have poorer prognosis compared to patients with either event alone ("single-hit"). The etiology for worse clinical outcomes in patients with "double-hit" cancers is unclear. We compared radiosensitivity of cell lines containing both TP53 mutations and deletion of Fragile Histidine Triad (FHIT, the gene most commonly associated with 3p deletion) to "single-hit" lines with only TP53 mutation. We compared radiosensitivity in a "single-hit" cell line with TP53 mutation converted to "double-hit" using RNA interference targeting FHIT. Finally, we compared matrixmetalloproteinase-2/9 (MMP-2/9) activity, a previously-established biomarker for tumor aggressiveness, in xenograft tumors derived from these cell lines. MATERIALS/ METHODS:TP53 mutation and FHIT deletion profiles of HNSCC lines were established using Cancer Cell Line Encyclopedia (CCLE). We used RNA-interference to convert a "single-hit" cell line (SCC4) to "double-hit". Cultured cells were examined for radiosensitivity and cisplatin sensitivity. MMP-2/9 activity was evaluated in "double-hit" versus "single-hit" tumors using ratiometric activatable cell-penetrating peptide (RACPP) in tongue (n=17) and flank xenografts (n=4). RESULTS: Radiotherapy caused greater double-stranded DNA breaks in "single-hit" vs naturally occurring and engineered "double-hit" cells. In-vivo, "double-hit" xenografts demonstrated higher MMP-2/9 activity compared to "single-hit" xenografts (p<0.01). There was no difference in cisplatin sensitivity between the cell lines. CONCLUSIONS:TP53 mutation combined with FHIT deletion correlates with decreased radiosensitivity in HNC cell lines. Xenograft from "double-hit" cells exhibit increased MMP-2/9 activity. These findings may in part account for the worse clinical outcome seen in patients with HNSCC "double-hit" tumors.
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Todd A Aguilera; Emilia S Olson; Margaret M Timmers; Tao Jiang; Roger Y Tsien Journal: Integr Biol (Camb) Date: 2009-05-11 Impact factor: 2.192
Authors: Samantha J Hauff; Sharat C Raju; Ryan K Orosco; Andrew M Gross; Julio A Diaz-Perez; Elamprakash Savariar; Nadia Nashi; Jonathan Hasselman; Michael Whitney; Jeffrey N Myers; Scott M Lippman; Roger Y Tsien; Trey Ideker; Quyen T Nguyen Journal: Otolaryngol Head Neck Surg Date: 2014-08-04 Impact factor: 3.497
Authors: Quyen T Nguyen; Emilia S Olson; Todd A Aguilera; Tao Jiang; Miriam Scadeng; Lesley G Ellies; Roger Y Tsien Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205
Authors: Andrew M Gross; Ryan K Orosco; John P Shen; Ann Marie Egloff; Hannah Carter; Matan Hofree; Michel Choueiri; Charles S Coffey; Scott M Lippman; D Neil Hayes; Ezra E Cohen; Jennifer R Grandis; Quyen T Nguyen; Trey Ideker Journal: Nat Genet Date: 2014-08-03 Impact factor: 38.330
Authors: Aman Khurana; Fanny Chapelin; Hongyan Xu; Joseph R Acevedo; Alfred Molinolo; Quyen Nguyen; Eric T Ahrens Journal: Magn Reson Med Date: 2017-07-26 Impact factor: 4.668
Authors: Dina V Hingorani; Jessica L Crisp; Matthew K Doan; Maria F Camargo; Maryam A Quraishi; Joseph Aguilera; Mara Gilardi; Larry A Gross; Tao Jiang; Wei T Li; Weg M Ongkeko; Ezra E W Cohen; J Silvio Gutkind; Stephen R Adams; Sunil J Advani Journal: Biomaterials Date: 2020-04-11 Impact factor: 15.304
Authors: Francesco Perri; Francesco Longo; Giuseppina Della Vittoria Scarpati; Salvatore Pisconti; Vito Longo; Raffaele Addeo; Fabio Carducci; Carlo Buonerba; Franco Fulciniti; Raffaele Solla Journal: Clin Case Rep Date: 2017-11-24